Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q891968> ?p ?o }
Showing triples 1 to 51 of
51
with 100 triples per page.
- Q891968 subject Q8341873.
- Q891968 subject Q8616810.
- Q891968 subject Q9536267.
- Q891968 abstract "Nabiximols (USAN, trade name Sativex) is a specific extract of Cannabis that was approved as a botanical drug in the United Kingdom in 2010 as a mouth spray for multiple sclerosis (MS) patients, who can use it to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms; it was developed by the UK company GW Pharmaceuticals. The drug is a pharmaceutical product standardised in composition, formulation, and dose. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a near 1:1 ratio of CBD to THC, with a fixed dose of 2.7 mg THC and 2.5 mg CBD. In May 2003 GW Pharmaceuticals and Bayer entered into an exclusive marketing agreement for GW’s cannabis-based medicinal extract product, to be marketed under the brand name Sativex. "Bayer has obtained exclusive rights to market Sativex in the UK. In addition, Bayer has the option for a limited period to negotiate the marketing rights in other countries in European Union and selected other countries around the world."In April 2011, GW licensed to Novartis the rights to commercialise nabiximols in Asia (excluding China and Japan), Africa and the Middle East (excluding Israel).".
- Q891968 atcPrefix "N02".
- Q891968 atcSuffix "BG10".
- Q891968 casNumber "56575-23-6".
- Q891968 pubchem "44148067".
- Q891968 thumbnail Tetrahydrocannabinol.svg?width=300.
- Q891968 wikiPageExternalLink www.gwpharm.com.
- Q891968 wikiPageWikiLink Q1033379.
- Q891968 wikiPageWikiLink Q1057591.
- Q891968 wikiPageWikiLink Q117060.
- Q891968 wikiPageWikiLink Q152051.
- Q891968 wikiPageWikiLink Q1776131.
- Q891968 wikiPageWikiLink Q182413.
- Q891968 wikiPageWikiLink Q190067.
- Q891968 wikiPageWikiLink Q1916302.
- Q891968 wikiPageWikiLink Q19903579.
- Q891968 wikiPageWikiLink Q269829.
- Q891968 wikiPageWikiLink Q3093459.
- Q891968 wikiPageWikiLink Q36.
- Q891968 wikiPageWikiLink Q3712728.
- Q891968 wikiPageWikiLink Q386434.
- Q891968 wikiPageWikiLink Q419079.
- Q891968 wikiPageWikiLink Q422917.
- Q891968 wikiPageWikiLink Q422936.
- Q891968 wikiPageWikiLink Q4926095.
- Q891968 wikiPageWikiLink Q507154.
- Q891968 wikiPageWikiLink Q7825858.
- Q891968 wikiPageWikiLink Q79817.
- Q891968 wikiPageWikiLink Q8277.
- Q891968 wikiPageWikiLink Q8341873.
- Q891968 wikiPageWikiLink Q8616810.
- Q891968 wikiPageWikiLink Q874632.
- Q891968 wikiPageWikiLink Q918396.
- Q891968 wikiPageWikiLink Q944760.
- Q891968 wikiPageWikiLink Q9536267.
- Q891968 wikiPageWikiLink Q967245.
- Q891968 atcPrefix "N02".
- Q891968 atcSuffix "BG10".
- Q891968 casNumber "56575".
- Q891968 pubchem "44148067".
- Q891968 type ChemicalSubstance.
- Q891968 type Drug.
- Q891968 type ChemicalObject.
- Q891968 type Thing.
- Q891968 type Q8386.
- Q891968 comment "Nabiximols (USAN, trade name Sativex) is a specific extract of Cannabis that was approved as a botanical drug in the United Kingdom in 2010 as a mouth spray for multiple sclerosis (MS) patients, who can use it to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms; it was developed by the UK company GW Pharmaceuticals. The drug is a pharmaceutical product standardised in composition, formulation, and dose.".
- Q891968 label "Nabiximols".
- Q891968 depiction Tetrahydrocannabinol.svg.